Point72 (DIFC)’s Pacira BioSciences PCRX Stock Holding History

Point72 (DIFC)’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,370	Closed	-$120K	–	1969
2024 Q4	$120K	Buy	+6,370	New	+$112K	﹤0.01%	967

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Point72 (DIFC)'s PCRX Position: Q1 2025 in Review

Point72 (DIFC) sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 6,370 shares — an estimated $120K sold.

Point72 (DIFC) first reported a position in PCRX in Q4 2024 and held it in 1 quarter. The position peaked at $120K in Q4 2024. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

Point72 (DIFC) reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
Point72 (DIFC) sold 6,370 Pacira BioSciences shares in Q1 2025, an estimated $120K.
Point72 (DIFC) first reported a position in Pacira BioSciences in Q4 2024 and held it in 1 quarter.
Point72 (DIFC)'s Pacira BioSciences position peaked at $120K in Q4 2024.
235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.